Division of Endocrinology and Metabolism, E-Da Hospital, Kaohsiung, 82445 Taiwan.
School of Medicine, College of Medicine, I-Shou University, Kaohsiung, 82445 Taiwan.
Int J Med Sci. 2020 Jan 14;17(2):182-190. doi: 10.7150/ijms.40417. eCollection 2020.
: Fatty acid-binding protein 1 (FABP1) (also known as liver-type fatty acid-binding protein or LFABP) is a protein that is mainly expressed in the liver, and is associated with hepatocyte injury in acute transplant rejection. Reduced levels of FABP1 in mice livers have been shown to be effective against nonalcoholic fatty liver disease (NAFLD). In this study, we investigated the association between plasma FABP1 levels and NAFLD in patients with type 2 diabetes mellitus (T2DM). : We enrolled 267 T2DM patients. Clinical and biochemical parameters were measured. The severity of NAFLD was assessed by ultrasound. FABP1 levels were determined using by enzyme-linked immunosorbent assays. : FABP1 levels were higher in patients with overt NAFLD, defined as more than a moderate degree of fatty liver compared to those without NAFLD. Age- and sex-adjusted analysis of FABP1 showed positive associations with body mass index (BMI), waist circumference, homeostasis model assessment estimate of β-cell function, creatinine, and fatty liver index, but showed negative associations with albumin and estimated glomerular filtration rate (eGFR). The odds ratio (OR) for the risk of overt NAFLD with increasing levels of sex-specific FABP1 was significantly increased (OR 2.63 [95% CI 1.30-5.73] vs. 4.94 [2.25-11.48]). The OR in the second and third tertiles of FABP1 remained significant after adjustments for BMI, triglycerides, high-density lipoprotein cholesterol, HbA1C, homeostasis model assessment estimate of insulin resistance, white blood cell count, hepatic enzymes, and eGFR. : Our results indicate that FABP1 may play a role in the pathogenesis of NAFLD in patients with T2DM.
脂肪酸结合蛋白 1（FABP1）（也称为肝型脂肪酸结合蛋白或 LFABP）是一种主要在肝脏中表达的蛋白质，与急性移植排斥反应中的肝细胞损伤有关。已经表明，小鼠肝脏中 FABP1 水平降低可有效对抗非酒精性脂肪性肝病（NAFLD）。在这项研究中，我们研究了 267 例 2 型糖尿病（T2DM）患者的血浆 FABP1 水平与 NAFLD 之间的关系。
我们招募了 267 例 T2DM 患者。测量了临床和生化参数。通过超声评估 NAFLD 的严重程度。使用酶联免疫吸附测定法测定 FABP1 水平。
与没有 NAFLD 的患者相比，有明显 NAFLD（定义为中度以上脂肪肝）的患者 FABP1 水平更高。对 FABP1 进行年龄和性别调整的分析显示，与体重指数（BMI）、腰围、β细胞功能的稳态模型评估估计值、肌酐和脂肪肝指数呈正相关，但与白蛋白和估计肾小球滤过率（eGFR）呈负相关。随着 FABP1 水平的升高，明显 NAFLD 的风险比（OR）显著增加（OR 2.63[95%CI 1.30-5.73]vs.4.94[2.25-11.48]）。在调整 BMI、甘油三酯、高密度脂蛋白胆固醇、HbA1C、胰岛素抵抗的稳态模型评估估计值、白细胞计数、肝酶和 eGFR 后，FABP1 的第二和第三三分位的 OR 仍然显著。
我们的研究结果表明，FABP1 可能在 T2DM 患者的 NAFLD 发病机制中起作用。
